Smith & Nephew Plc Director/PDMR Shareholding

RNS Number : 7714L

Smith & Nephew Plc

11 November 2024

 

SMITH & NEPHEW PLC

 

11 November 2024

 

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

 

Reason for the notification
Initial notification /Amendment	Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name	Smith & Nephew plc
LEI	213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument	Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code	ISIN: GB0009223206
Nature of the transaction	Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2024 interim dividend payment on 8 November 2024.
Date of Transaction	2024 - 11 - 08
Place of Transaction	London Stock Exchange (XLON)

 

Name (Position)	Director / PDMR	Price	Volume	Aggregated information
Helen Barraclough (Group General Counsel and Company Secretary)	PDMR	9.234	421.23522	N/A Single Transaction
Paul Connolly (President, Global Operations)	PDMR	9.234	194.91162	N/A Single Transaction
Phil Cowdy Chief Corporate Development & Corporate Affairs Officer	PDMR	9.234	1.9035	N/A Single Transaction
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer)	PDMR	9.234	111.64316	N/A Single Transaction
Deepak Nath (Chief Executive Officer)	Director	9.234	1924.20518	N/A Single Transaction
Scott Schaffner (President, Sports Medicine)	PDMR	9.234	794.95718	N/A Single Transaction

 

 

 

 

Helen Barraclough

General Counsel and Company Secretary

Smith & Nephew plc

 

Tel:  [phone]

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

DSHFLFSRLVLLLIS